ZURA BIO LIMITED Proceeds from Notes Payable
ZURA BIO LIMITED (ZURA) reported Proceeds from Notes Payable of $7.60 million for the 11-month period ending 2022-12-31, per its 10-K filed 2024-03-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2024-03-28
- 2022-12-31: Proceeds from Notes Payable 11 month $7.60M.
- 2022-06-30: Proceeds from Notes Payable 6 month $179.01K.
| Period end | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 11 month |
|---|---|---|
| 2022-12-31 | $7.60M 10-K · filed 2024-03-28 | |
| 2022-06-30 | $179.01K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |